Pfizer Inc
NYSE:PFE

Watchlist Manager
Pfizer Inc Logo
Pfizer Inc
NYSE:PFE
Watchlist
Price: 25.85 USD 0.19% Market Closed
Market Cap: 147B USD

Intrinsic Value

The intrinsic value of one PFE stock under the Base Case scenario is 29.61 USD. Compared to the current market price of 25.85 USD, Pfizer Inc is Undervalued by 13%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

PFE Intrinsic Value
29.61 USD
Undervaluation 13%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Pfizer Inc

What is Valuation History?
Ask AI Assistant
What other research platforms think about PFE?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is PFE valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Pfizer Inc.

Explain Valuation
Compare PFE to

Fundamental Analysis

Company Overview
Loading...
Business Segments
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
Bear Theses

Pfizer’s revenue from its COVID-19 vaccine may sharply fall as the pandemic fades, creating reliance on a still-emerging pipeline that may struggle to offset the loss of high-margin vaccine income.

Patent expirations on blockbuster drugs like Ibrance and Xeljanz pose a significant threat to long-term sales growth, as cheaper generics or biosimilars could rapidly erode market share.

Amid rising scrutiny over drug pricing and intensifying regulatory efforts in major markets, Pfizer's historically premium-priced portfolio may face margin pressure and unpredictable pricing environments.

Bull Theses

A robust late-stage pipeline in immunology, oncology, and vaccine segments could yield multiple blockbuster approvals, helping Pfizer not only offset patent-cliff losses but also drive new revenue growth.

The company’s healthy balance sheet and solid cash flows enable strategic acquisitions of smaller biotech innovators, bolstering Pfizer’s R&D capabilities and strengthening its future product portfolio.

Pfizer’s successful collaboration with BioNTech on the COVID-19 vaccine highlights growing expertise in mRNA technology, positioning the firm to capitalize on novel treatments and next-generation vaccines beyond the pandemic.

Show More Less
How do you feel about PFE?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Pfizer Inc

Current Assets 46.9B
Cash & Short-Term Investments 15B
Receivables 18.1B
Other Current Assets 13.8B
Non-Current Assets 161.8B
Long-Term Investments 2.1B
PP&E 18.9B
Intangibles 120.4B
Other Non-Current Assets 20.4B
Current Liabilities 36.6B
Accounts Payable 5B
Accrued Liabilities 3B
Short-Term Debt 56m
Other Current Liabilities 28.5B
Non-Current Liabilities 79.3B
Long-Term Debt 57.4B
Other Non-Current Liabilities 21.9B
Efficiency

Free Cash Flow Analysis
Pfizer Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Pfizer Inc

Revenue
62.8B USD
Cost of Revenue
-15.7B USD
Gross Profit
47.1B USD
Operating Expenses
-28.8B USD
Operating Income
18.3B USD
Other Expenses
-8.5B USD
Net Income
9.8B USD
Fundamental Scores

PFE Profitability Score
Profitability Due Diligence

Pfizer Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin
Healthy Operating Margin
Strong 3Y Average Gross Margin
Sustainable 3Y Average Operating Margin
51/100
Profitability
Score

Pfizer Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.

PFE Solvency Score
Solvency Due Diligence

Pfizer Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Average Altman Z-Score
45/100
Solvency
Score

Pfizer Inc's solvency score is 45/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

PFE Price Targets Summary
Pfizer Inc

Wall Street analysts forecast PFE stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for PFE is 29.69 USD with a low forecast of 24.24 USD and a high forecast of 39.42 USD.

Lowest
Price Target
24.24 USD
6% Downside
Average
Price Target
29.69 USD
15% Upside
Highest
Price Target
39.42 USD
52% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for PFE is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

Ownership

PFE Insider Trading
Buy and sell transactions by insiders

PFE News

Other Videos
What is the Intrinsic Value of one PFE stock?

The intrinsic value of one PFE stock under the Base Case scenario is 29.61 USD.

Is PFE stock undervalued or overvalued?

Compared to the current market price of 25.85 USD, Pfizer Inc is Undervalued by 13%.

Back to Top